Mark T. Roundtree is an associate in Sterne Kessler’s Biotechnology & Chemical Practice Group.

Prior to attending law school, Mark earned his M.S. in Immunology and Infectious Disease in the Department of Microbiology, Immunology & Molecular Genetics at UT Health San Antonio. While working toward his M.S., Mark researched the effect of deletion, suppression, and overexpression of genes controlling the cellular morphology of Candida species.

Mark subsequently earned an M.S. in Molecular Genetics and Microbiology from Duke University. While at Duke, Mark researched antifungal drug targets in the opportunistic fungal pathogen Aspergillus fumigatus. In particular, Mark researched how the expression and intracellular localization of the Aspergillus fumigatus azole drug targets Cyp51A and Cyp51B shifted in response to azole-induced stress.

Mark received his J.D. from the Texas A&M University School of Law, where he served as a staff member and Notes & Comments Editor for the Texas A&M Law Review. During his fall 2023 semester, Mark worked as a clinic student in the Texas A&M University School of Law Patent Clinic.

Technical Publications:

  • Roundtree, M.T., et al. (2020), Aspergillus fumigatus Cyp51A and Cyp51B Proteins Are Compensatory in Function and Localize Differentially in Response to Antifungals and Cell Wall Inhibitors, Antimicrobial Agents and Chemotherapy.

  • J.D., Texas A&M University School of Law
  • M.S., Molecular Genetics and Microbiology, Duke University
  • M.S., Immunology and Infectious Disease, University of Texas Health Science Center at San Antonio
  • B.S., Microbiology, University of Oklahoma

  • Texas